Previous studies focusing on EDA- and EDB-containing FN (EDA-FN and EDB-FN, respectively) in human tumor specimens have found them to be aberrantly expressed in several cancers, including breast cancer, head and neck cancer, pancreatic cancer, and prostate cancer, among others [19,20,21,22,23,24,25]. The gene discussed is FN1; the disease is prostate cancer.